October 25, 2014 11:14 PM ET


Company Overview of GlycoMimetics, Inc.

Company Overview

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company develops lead product GMI-1070, a glycomimetic drug candidate that has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. It also develops GMI-1271, a specific E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers; and GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a co...

401 Professional Drive

Suite 250

Gaithersburg, MD 20879

United States

Founded in 2003

27 Employees





Key Executives for GlycoMimetics, Inc.

Age: 55
Total Annual Compensation: $365.7K
Chief Financial Officer
Age: 40
Total Annual Compensation: $216.7K
Chief Medical Officer and Vice President of Clinical Development
Age: 46
Total Annual Compensation: $337.8K
Chief Scientific Officer
Age: 61
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2013.

GlycoMimetics, Inc. Key Developments

GlycoMimetics, Inc Announces Delay in the Initiation of the Phase 3 Trial with Rivipansel

GlycoMimetics, Inc. announced that it has been informed by Pfizer that initiation of its Phase 3 clinical trial with rivipansel (GMI-1070) will be significantly delayed due to a manufacturing development issue impacting formulated drug supply. Pfizer advised GlycoMimetics that the issue is under review and Pfizer is working diligently to remedy the situation. Pfizer also noted that upon identifying the specific cause and associated remedy of the manufacturing issue, Pfizer will advise GlycoMimetics of a more specific timeframe regarding the commencement of the Phase 3 study.

BioMed Realty Signs New Lease with GlycoMimetics at its Newly Redeveloped Center for Life Science | Shady Grove Campus in Rockville, Maryland

BioMed Realty Trust, Inc. announced the signing of a new lease with GlycoMimetics, Inc. for one building comprising approximately 33,800 square feet at the Center for Life Science | Shady Grove in Rockville, Maryland. GlycoMimetics will be moving to the Center for Life Science | Shady Grove, a four building campus with approximately 214,700 square feet or laboratory and office space. The campus is located along the I-270 Corridor in Montgomery County, also known as 'DNA Alley,' which supports several large-scale federal government health agencies, including the Food and Drug Administration, the National Institutes of Health, the Department of Homeland Security and the National Cancer Institute. The area is also home to several world-renowned universities and research institutes, including Johns Hopkins University, the University of Maryland and the Howard Hughes Medical Institute. 77 million dollors.

GlycoMimetics, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 09:00 AM

GlycoMimetics, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 09:00 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States. Speakers: Rachel K. King, Founder, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
CellExSys, Inc. United States
Nodality, Inc. United States
Glycobia, Inc. United States
Cytogam, Inc. United States
MORPHOTEK INC. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GlycoMimetics, Inc., please visit www.glycomimetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.